培美曲塞+奈达铂联合贝伐珠单抗治疗后行培美曲塞联合贝伐珠单抗维持治疗在晚期非鳞非小细胞肺癌中的疗效与安全性分析

Efficacy and Safety of Pemetrexed,Nedaplatin and Bevacizumab Combination Therapy Followed by Pemetrexed and Bevacizumab Maintenance Therapy in Advanced Nonsquamous Non-small Cell Lung Cancer

目的观察培美曲塞+奈达铂联合贝伐珠单抗治疗后培美曲塞联合贝伐珠单抗维持治疗方案在晚期非鳞非小细胞肺癌患者中的疗效和安全性,并探讨影响该化疗方案疗效的相关因素。方法收集2015年6月—2018年6月经病理确诊的50例晚期非鳞非小细胞肺癌患者,所有患者均接受培美曲塞+奈达铂联合贝伐珠单抗治疗,并对治疗后疾病未进展的患者给予培美曲塞联合贝伐珠单抗维持治疗,直至疾病进展或出现不可耐受的不良反应。对患者的近期疗效和不良反应进行分析。结果50例患者的客观缓解率(ORR)和疾病控制率(DCR)分别为42%(21/50)和86%(43/50),中位无进展生存期(PFS)为11个月(95%CI:8.1~13.9)。治疗相关不良反应主要为骨髓抑制,但均可耐受,无不良反应相关性死亡。结论培美曲塞+奈达铂联合贝伐珠单抗治疗后培美曲塞联合贝伐珠单抗维持化疗方案在晚期非鳞非小细胞肺癌患者中有较好的疗效和安全性。

Objective To evaluate the efficacy and safety of pemetrexed plus bevacizumab and nedaplatin combination therapy followed by pemetrexed and bevacizumab maintenance therapy in patients with advanced nonsquamous non-small lung cancer,and to explore the related factors affecting the efficacy of this chemotherapy regimen.Methods A total of 50 advanced nonsquamous non-small lung carcinoma patients confirmed by histopathology between June 2015 and June 2018 were analyzed retrospectively.All patients received the combination chemotherapy of pemetrexed,nedaplatin and bevacizumab.Patients with no disease progression after combination chemotherapy were given pemetrexed and bevacizumab maintenance therapy until disease progression or intolerable adverse reactions occurred.Analyze the short-term efficacy and adverse reactions of the patients.Results The objective response rate(ORR)and disease control rate(DCR)was respectively 42%(21/50)and 86%(43/50).The median progression-free survival(PFS)was 11 months(95%CI:8.1~13.9).The related adverse drug reaction was mainly bone marrow suppression,but it was well-tolerated.There was no adverse drug reactions-related death.Conclusion The pemetrexed and bevacizumab maintenance therapy after combination chemotherapy of pemetrexed,nedaplatin and bevacizumab had good efficacy and safety in patients with advanced nonsquamous non-small lung cancer.